問題 › 顧客を増やすには › HealthTech & Digital Health
登録会員の増加は結果です。選択すべきは、成果に基づく収益シェアが回収期間を超えない範囲で繰り返せる経路です。 デジタルヘルス企業特有の制約は、成果リスクを負う契約が、負担可能かどうかを確認できる期間より早く結ばれる点にあります。測定期間12ヶ月に対し営業サイクル11ヶ月という構造です。このリスクが価格に織り込まれない限り、成果連動型収益シェアは原因の特定できない変動を続け、チャネル別CACの議論は意見の域を出ません。
登録会員の増加は結果です。選択すべきは、成果に基づく収益シェアが回収期間を超えない範囲で繰り返せる経路です。 デジタルヘルス企業特有の制約は、成果リスクを負う契約が、負担可能かどうかを確認できる期間より早く結ばれる点にあります。測定期間12ヶ月に対し営業サイクル11ヶ月という構造です。このリスクが価格に織り込まれない限り、成果連動型収益シェアは原因の特定できない変動を続け、チャネル別CACの議論は意見の域を出ません。
ほとんどのデジタルヘルス企業は会員登録の方法をいくつか挙げられますが、測定期間終了後にどの方法が回収しているかを示せる企業は少ないです。本当の制約は戦術の不足ではなく、収益がエンゲージメント率とロゴチャーンに連動する場合にどの戦術を増やすかの根拠がない点です。
有効な枠組みは経路の経済性です。各経路について、成果連動型収益シェアまたはPMPMで1名の登録会員を獲得する費用、成果から粗利益がその費用を回収するまでの期間、規模拡大時に費用が上昇せずに繰り返せるかどうかを問います。
ほとんどの経路は3番目の条件を満たしません。CEOやCFOと payers や providers の関係に依存するため初期登録は得られますが、その注意が次の契約へ移ると途切れます。
この3つが揃うと特徴的です。1つだけでは別のことを示すことが多いです。
✓ 登録会員の増加が、CRMで確認できる反復プロセスではなくCEOまたはCFOのカレンダーと連動しています。
✓ 登録会員1名あたりの費用が経路別や成果連動型収益シェアで回収された部分の内訳なく、集計PMPMのみで表示されています。
✓ 複数のチャネルでパイロットが同時に進行している一方、エンゲージメント率とロゴチャーンは横ばいです。いずれの経路も成果を測定できる規模に達していないためです。
通常、事態を悪化させる対応です。 複数の獲得経路を小規模で同時に運用することです。各経路でエンゲージメント率と成果連動型収益シェアの結果が不明確なまま、総支出が単一経路の検証速度を上回ります。
It is for you if you run or finance a digital health company and growth depends on one person's relationships. It is the situation where the numbers are available but nobody has put them in an order that produces a decision.
It is not for you if Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Below is an excerpt from a real run of this analysis on デジタルヘルス企業. It is a sample profile rather than a customer, and it is engine output translated from English — this is the format you get, on your own numbers.
The subject is Vantabridge Health, a sample company profile used for testing rather than a customer — $62M ARR, 340,000 enrolled members.
Excerpt from a real Percision run · Pricing Strategy · sample company profile
The move. Convert 180 existing employer relationships into $11.7M incremental outcomes-contingent revenue by Month 24 without new-plan procurement.
The leak it closes. $6.5M device leakage reduced by shifting kit cost to employer opt-in, improving gross margin 7 points on employer cohort
The assumption it rests on. 180 employers accept outcomes-contingent terms at 45% at-risk share — the engine put the probability at 0.7.
| Investment required | $0.6–0.9M total (2 FTE employer specialists @ $180K fully loaded each × 18 months + $120K enablement tools) |
| Expected return | 13.0× on $0.9M investment ($11.7M incremental revenue by Month 24) |
| Revenue, year 1 | $3.9M incremental employer outcomes revenue |
| Revenue, year 2 | $11.7M cumulative incremental employer outcomes revenue |
| Revenue, year 3 | $18.5M cumulative if employer cohort grows 15% YoY |
| Exit criteria | Terminate move if employer conversion rate <25% by Month 12 OR if employer at-risk share demanded exceeds 50% OR if device-kit leakage reduction <10 points by Month 18. |
This is one move out of a full analysis. Read a complete report — every page, no email required.
This question routes to Go-to-Market & Commercial Strategy, one of 29 engagements the platform runs. For デジタルヘルス企業 it works through at-risk revenue share, engagement rate, gross margin and logo churn, then produces the sequence rather than a list of options — which move first, what it funds, and the observation that would say the sequence is wrong.
You watch the analysis get built before paying anything. 完全なレポートはこちらをご覧ください if you would rather see the depth first.
買い手がすでに存在し、獲得費用を自社で融資可能な期間内に回収できるチャネルです。これは事業ごとに異なり、一般論はほとんど役に立ちません。
まず1つを成立させ、次に2つ目です。必要予算の4分の1で4チャネルを同時に走らせると、4つの不明確な結果と「どれも機能しない」という結論が生まれます。
自社の営業サイクルに回収期間を加え、結果をノイズと区別できる十分な規模を確保した期間です。この数値を事前に定めることで、説得力のある人物の意見で判断が左右されるのを防げます。
Materially, yes. Outcomes risk is being signed faster than the company can learn whether it can carry it — a 12-month measurement window against an 11-month sales cycle — which changes both the diagnosis and the order of the fixes. The metrics that decide it here are at-risk revenue share, engagement rate, gross margin, and an answer built on industry-general benchmarks will usually point at the wrong one first.
Less than most people expect. Your last twelve months of revenue and cost split the way you already split it, plus whatever you hold on at-risk revenue share and engagement rate. The analysis is explicit about what it is assuming where your data stops, which is more useful than waiting for numbers you may never have.
Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Describe the situation in your own words and we will tell you which analysis answers it — before you sign up for anything.
Describe my situation →Prefer to skip ahead? Go straight to the free diagnostic.
English · Español · Deutsch · Português · Français · Italiano · Nederlands · 日本語 · 한국어 · 中文 · Polski · Svenska · Türkçe · العربية · Tiếng Việt · ไทย · हिन्दी · עברית